X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 54 filers reported holding X4 PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,273,000 | -39.6% | 565,804 | -35.2% | 0.50% | -54.6% |
| Q1 2020 | $8,732,000 | +13.3% | 873,215 | +21.3% | 1.09% | +72.0% |
| Q4 2019 | $7,704,000 | +1179.7% | 720,000 | +1419.3% | 0.64% | +582.8% |
| Q3 2019 | $602,000 | -15.3% | 47,391 | 0.0% | 0.09% | -4.1% |
| Q2 2019 | $711,000 | – | 47,391 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |